About

We want to do more than just treat monogenic CNS disease. We want to eradicate it.

Who We Are

At Taysha Gene Therapies, we believe the patient always comes first.

This is why we are singularly focused on discovering, developing and commercializing gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), both in rare and large patient populations.

We were founded in partnership with The University of Texas Southwestern Medical Center (UT Southwestern) to develop and commercialize transformative gene therapy treatments. Together with UT Southwestern, we have created a powerful engine to develop transformative therapies with the potential to dramatically improve patients’ lives.

We are rooted in the heart of Dallas, not far from the iconic Spindletop oil field.

Through the generations, these hardworking explorers ultimately went on to fund the very research being conducted at UT Southwestern today.

At Taysha, we embrace the same diligent, trailblazing mindset our Texan ancestors were known for.

As the largest oil production center at the turn of the century, Spindletop fueled Texas’ economy and a new breed of ‘wildcatters’ – the individuals who drilled new, exploratory oil wells.

UT Southwestern Partnership

Our partnership with UT Southwestern is different from traditional collaborations between industry and academia.

Through our partnership, we are able to leverage the collective expertise of UT Southwestern researchers, clinicians and investigators with decades of experience in conducting cutting-edge research and providing clinical care. This includes the esteemed scientists who lead the UT Southwestern Gene Therapy Program: Steven Gray, Ph.D., and Berge Minassian, M.D.

We have access to UT Southwestern’s faculty, GMP viral vector manufacturing facility and integrated research and clinical care approach. Together, we believe this will enable us to advance our development programs with speed and scale.

UT Southwestern is one of the premier academic medical centers in the nation. Collectively, its faculty has earned some of the most prestigious honors in science.

6

Nobel Prize Winners

24

Members of the National Academy of Sciences

16

Members of the National Academy of Medicine

13

Howard Hughes Medical Institute Investigators

Our Team

We’ve assembled the experts.

Our team is comprised of some of the most accomplished and knowledgeable gene therapy scientists and CNS disease experts. Together – armed with our unrelenting, patient-first focus – we are helping bring new cures to life.

Leadership Team

Kamran Alam, CPA, MBA

Chief Financial Officer

Fred Porter, Ph.D.

Chief Technical Officer

Emily McGinnis

Chief Patient Officer and Head of Government Affairs

Mishima Gerhart

Chief Regulatory Officer and Head of Quality

Sean McAuliffe

Chief Commercial Officer

Jim Rouse

Chief Information Officer

Dan Janiak, Ph.D.

SVP of Corporate Strategy and Business Development

Niren Shah, Pharm.D., MBA

VP of Business Operations and Chief of Staff

Board of Directors

Sean Nolan

Nolan Capital (Chairman)

Paul Manning

PBM Capital

Phillip Donenberg, CPA

Former Chief Financial Officer, AveXis

Sukumar Nagendren, M.D.

Former Chief Medical Officer, AveXis

Kathy Reape, M.D.

Former Chief Medical Officer, Spark Therapeutics

Laura Sepp-Lorenzino, Ph.D.

Chief Scientific Officer, Intellia Therapeutics

Advisors

Steven Gray, Ph.D.

Chief Scientific Advisor
UT Southwestern Gene Therapy Program

Berge Minassian, M.D.

Chief Medical Advisor
UT Southwestern Gene Therapy Program

Copyright 2020- Taysha GTx